2020
DOI: 10.1016/j.ekir.2020.09.010
|View full text |Cite
|
Sign up to set email alerts
|

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)

Abstract: Introduction: The clinical trial on the Development of a treatment strategy for chronic kidney diseasemineral and bone disorder by a mUltilateral mechanism of ETelcalcetide hydrochloride, or the DUET trial, was designed to determine the efficacy of etelcalcetide, an intravenous calcimimetic, for control of secondary hyperparathyroidism (SHPT). Methods: Eligible SHPT maintenance hemodialysis patients (n ¼ 124) were randomized (1:1:1) for inclusion in the DUET trial, a 12-week, multicenter, open-label, parallel-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 20 publications
2
5
0
Order By: Relevance
“…13 We also confirmed the advantage of active vitamin D in correcting hypocalcaemia and superiority of oral calcium preparation for suppression of hyperphosphatemia, when evaluating which it was better to load vitamin D or oral calcium preparation for correction of hypocalcaemia. 13 Some studies have reported that FGF23 levels decrease in parallel with iPTH levels during SHPT treatment treated with vitamin D and calcimimetics. 14,15 To date, few reports have focused on changes in FGF23 levels by comparing correction drugs for hypocalcaemia, 16 and no study has evaluated CPP levels during treatment with etelcalcetide.…”
Section: Introductionsupporting
confidence: 68%
See 4 more Smart Citations
“…13 We also confirmed the advantage of active vitamin D in correcting hypocalcaemia and superiority of oral calcium preparation for suppression of hyperphosphatemia, when evaluating which it was better to load vitamin D or oral calcium preparation for correction of hypocalcaemia. 13 Some studies have reported that FGF23 levels decrease in parallel with iPTH levels during SHPT treatment treated with vitamin D and calcimimetics. 14,15 To date, few reports have focused on changes in FGF23 levels by comparing correction drugs for hypocalcaemia, 16 and no study has evaluated CPP levels during treatment with etelcalcetide.…”
Section: Introductionsupporting
confidence: 68%
“…Characteristics of the patients enrolled to the DUET study at baseline was described in the main paper 13 and in Supporting Information, Table S1.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations